Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy

Glaysher, S; Gabriel, FG; Johnson, P; Polak, M; Knight, LA; Parker, K; Poole, M; Narayanan, A; Cree, IA; NHS Collaborative Research Programme for Predictive Oncology

doi:10.1038/sj.bjc.6605817

Glaysher, S; Gabriel, FG; Johnson, P; Polak, M; Knight, LA; Parker, K; Poole, M; Narayanan, A; Cree, IA; NHS Collaborative Research Programme for Predictive Oncology

Abstract

Ovarian cancer shows considerable heterogeneity in its sensitivity to chemotherapy both clinically and in vitro. This study tested the hypothesis that the molecular basis of this difference lies within the known resistance mechanisms inherent to these patients' tumours.

Keywords

Antineoplastic combined chemotherapy protocols; Busulfan; Cisplatin; Deoxycytidine; Drug resistance; Neoplasm; Drug screening assays; Antitumor; Female; Humans; Ovarian neoplasms; Topotecan

Date

August 24, 2010

Source

Br J Cancer, vol.103(5), pp.656 - 662

Item Type

Journal Article

Publisher

Nature Publishing Group

DOI

10.1038/sj.bjc.6605817

Publisher's Version

http://dx.doi.org/10.1038/sj.bjc.6605817

Rights Statement

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.